Physician profile
Stacey V Eason
NPI 1306481189
$3,186.91
in general payments reported to CMS, 2019-2025
31 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $399 · 2023: $410 · 2024: $731 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,362.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $868.38 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $271.97 | 2024-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $261.33 | 2024-2025 | Auvelity |
| Corium, LLC | $220.90 | 2024-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $203.69 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $163.36 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $148.92 | 2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $125.76 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $98.67 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $92.60 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Neos Therapeutics, LP | $91.09 | 2024-2025 | Adzenys Xr-Odt |
| Novo Nordisk INC | $76.31 | 2022-2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $69.14 | 2022-2023 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $62.95 | 2023-2024 | Quviviq |
| Amgen INC. | $53.31 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $40.47 | 2024-2025 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $37.50 | 2025 | Austedo Xr |
| Daiichi Sankyo INC. | $35.61 | 2021 | |
| Myovant Sciences INC. | $33.42 | 2021 | |
| Ironshore Pharmaceuticals INC. | $31.61 | 2024 | |
| Therapeuticsmd, INC. | $29.47 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.97 | 2022-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $21.11 | 2025 | Jornay Pm |
| Alkermes, INC. | $18.61 | 2025 | Aristada, Lybalvi |
| Mylan Pharmaceuticals INC. | $16.08 | 2021 | |
| Exeltis, USA INC. | $15.40 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.98 | 2023 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $14.82 | 2022 | |
| Sage Therapeutics, LLC | $14.71 | 2022 | |
| Neurocrine Biosciences, INC. | $13.75 | 2025 | |
| Pfizer INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Eason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.